SURMOUNT-3: what tirzepatide added after a 12-week lifestyle programme

SURMOUNT-3 asked what tirzepatide adds once someone has already lost weight through diet and activity. After a 12-week intensive lifestyle programme, average weight fell a further 18.4% over 72 weeks on tirzepatide, while the placebo group gained 2.5% [1]. The trial enrolled only people who had lost at least 5% first, so it describes a pre-selected group.

Why this study matters

Most tirzepatide trials start people on the drug from their usual weight. SURMOUNT-3 tests a different order of events: lifestyle programme first, medicine second. The authors note that the effect of tirzepatide on weight reduction after successful intensive lifestyle intervention was unknown before this trial [1].

We cover the drug as a whole in our tirzepatide evidence guide and the first obesity trial in SURMOUNT-1. The diabetes-population result is in SURMOUNT-2. This page takes the lifestyle-first trial on its own.

What they did

Of 972 adults assessed, 806 entered a 12-week intensive lifestyle programme. Adults had a BMI of 30 or more, or 27 or more with at least one obesity-related complication, and no diabetes. Those who lost 5% or more of body weight were randomised to tirzepatide at the maximum tolerated dose of 10 mg or 15 mg, or to placebo, once weekly for 72 weeks [1].

Of the 579 randomised, 287 received tirzepatide and 292 received placebo. During the lead-in they had lost an average of 7.6 kg, about 6.9% of body weight, bringing mean weight at randomisation to 101.9 kg [1]. The 17.5% of lead-in participants who did not lose 5% were not randomised [1].

The two co-primary end points were the further percentage change in body weight from randomisation to week 72 and the share of people achieving a further reduction of 5% or more. The main analysis used the treatment-regimen estimand, which assesses effects regardless of treatment adherence in the intention-to-treat population [1].

What they found

Both co-primary end points were met, with P below 0.001 for each. The odds ratio for reaching a further 5% reduction was 34.6 (95% CI 19.2 to 62.6) [1].

The placebo group regained weight on average. That fits the way the trial was built: everyone had just lost weight in a structured programme, and the placebo arm shows what happened to that group when no medicine followed. The authors conclude that tirzepatide provided substantial additional reduction in body weight in participants who had already achieved at least 5.0% with lifestyle intervention [1].

Treatment completion differed. Overall 78.7% of the tirzepatide group and 69.5% of the placebo group completed the study on treatment [1].

Safety reported

Gastrointestinal events were the most common. They occurred in more people on tirzepatide than on placebo, were mostly mild to moderate, and occurred mainly during dose escalation [1].

One death occurred in each group [1]. Antiemetic medicines were used by 27.2% of the tirzepatide group and 6.8% of the placebo group [1].

Caveats

• Sponsor. Eli Lilly and Company funded the trial, and several authors are Lilly employees and shareholders [1].
• Selected group. Only people who lost 5% or more in the lead-in were randomised, so the result does not describe people who respond less to a lifestyle programme [1].
• Who was in it. 86.0% of participants were White and 53.9% were Hispanic or Latino. The trial ran only in the US, Brazil and Argentina, which the authors name as a limit on generalisability [1].
• Tolerability measures. Dose reductions and re-escalation were allowed during the first 24 weeks, which the authors describe as a way to maximise tolerability. Real-world dosing may differ [1].

What it means in practice

The practical reading is about order and size. In this trial, a structured lifestyle programme produced a modest first step, and tirzepatide produced a much larger second step in the people who were randomised to it. The placebo arm did not keep losing. This is a trial result for a defined group over 72 weeks. It gives no guidance on starting, stopping or dosing any medicine, and those decisions sit with a prescriber who knows the person's history.

How it sits next to SURMOUNT-1

SURMOUNT-1 reported a 20.9% average weight reduction at 15 mg over 72 weeks in adults without diabetes who started from their usual weight [2]. The 18.4% here is a different measurement. It counts only the change after randomisation, on top of the roughly 6.9% already lost in the lead-in [1]. The two figures use different starting points, so they should not be set against each other as a ranking of the trials.

What is still open

• How weight changes after the 72-week mark in people who stop.
• How people who lose less than 5% on a lifestyle programme respond to the same drug.
• How the result looks in groups under-represented here, including people outside the Americas.

What this means

We read SURMOUNT-3 as a well-run, manufacturer-funded randomised trial showing that tirzepatide produced a large further weight reduction in adults who had already lost weight through lifestyle change: 18.4% against a 2.5% gain on placebo [1]. The result applies to people who cleared a 5% threshold first. To disagree with that reading, you would need a comparable randomised trial in this population showing no difference from placebo, and this page does not rely on one.

Educational content only — not medical advice. Many peptides discussed on HPR are not approved for human use. Talk to a qualified clinician before making any decision about your health.